Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Up 4.6 %

Shares of NASDAQ ADXS traded up $0.02 during mid-day trading on Thursday, hitting $0.56. 1,601 shares of the company traded hands, compared to its average volume of 19,446. Ayala Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $1.95. The stock has a market capitalization of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.63. The business has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.73.

Ayala Pharmaceuticals (NASDAQ:ADXSGet Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Featured Stories

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.